JPM 2026 was touted as the event that would usher in the best year in biotech in a long time. But when it happened there was a distinct lack of mega-deals to shout about. The elephant, you might say, was not in the room. Does this bode ill for 2026? Or is news of such […]
There’s a temptation to think we won’t need Dry January or Love Your Liver Month initiatives in the future. After all, alcohol consumption is declining across the West and has been doing so for the last two decades. Gen Z teens rebel against their Gen X parents by not drinking – and castigating their elders for their unhealthy ways. In the UK only 7% […]
People in Europe and the US rarely pay for prescription drugs out of their own pockets. In Europe, their national health services almost always pick up the tab – even if some people have to contribute by way of a prescription charge. In the US, the health insurer normally foots the bill. But things have […]
You have probably already seen the news: not one but two major European life science funds have closed in the last week – collectively raising a massive €1.15 billion! Last Friday (November 14), leading European life sciences venture capital firm Medicxi announced it had closed its €500 million Medicxi V fund. And on Monday, (November […]
You’d expect us here at Optimum Strategic Communications to be excited about Nobel Prize season – particularly the gongs for the two categories of Physiology or Medicine and Chemistry. And we have been. But it’s this year’s Nobel Prize for Economic Sciences that really caught our eye, because it has major implications for the life […]
